Current Treatment Options in Neurology

, Volume 11, Issue 3, pp 193–202 | Cite as

Clinically isolated syndrome and multiple sclerosis: Rethinking the arsenal


Opinion statement

Until the end of the past century, a diagnosis of multiple sclerosis (MS) was often accompanied by a sense of apprehension, fueled primarily by the lack of available therapies and failed attempts with numerous agents. The modern era of MS therapeutics introduced in the past 20 years has helped to assuage the previous belief that little could be done to treat MS. The advent of disease-modifying treatments such as interferons and glatiramer acetate has had a notable impact on the course of MS. Numerous trials have demonstrated the clear benefit of initiating therapy in patients with a diagnosis of MS, but more importantly, they have shown that early initiation of treatment can delay progression to clinically definite MS in patients with clinically isolated syndrome who have concurrent changes on MRI. As newer agents become available, trials to assess their efficacy and tolerability are under way in an effort to expand the arsenal of available treatments. However, questions constantly resurface about the effect of treatments on disability, the safety of combination therapies, the role in neuroprotection, and other aspects. Moreover, recent attention regarding a radiologic and clinical dissociation, best illustrated by the anecdotally termed “radiologically isolated syndrome,” highlights the frustrations facing clinicians when they try to predict disease course and the role of medications, if any.

Despite the need for clear answers to these questions, the current practice is to initiate the available treatments early in patients with relapsing-remitting multiple sclerosis, in order to reduce the severity and frequency of clinical relapses. Treatment should also be initiated early in patients with clinically isolated syndrome because they are at high risk for developing clinically definite multiple sclerosis.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Orton SM, Herrera BM, Yee, IM, et al.: Sex ratio of multiple sclerosis in Canada: a longitudinal study. Lancet Neurol 2006, 5:932–936.PubMedCrossRefGoogle Scholar
  2. 2.
    Richards RG, Sampson FC, Beard SM, Tappenden P: A review of the natural history and epidemiology of multiple sclerosis: implications for resource allocation and health economic models. Health Technol Assess 2002, 6:1–73.PubMedGoogle Scholar
  3. 3.
    Polman CH, Reingold SC, Edan G, et al.: Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria.” Ann Neurol 2005, 58:840–846.PubMedCrossRefGoogle Scholar
  4. 4.
    Confavreux C, Aimard G, Devic M: Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 1980, 103:281–300.PubMedCrossRefGoogle Scholar
  5. 5.
    Poser S, Bauer HJ, Poser W: Prognosis of multiple sclerosis: results from an epidemiological area in Germany. Acta Neurol Scand 1982, 65:347–354.PubMedCrossRefGoogle Scholar
  6. 6.
    Weinshenkar BG, Bass B, Rice GP, et al.: The natural history of multiple sclerosis: a geographically based study. 1. Clinical course and disability. Brain 1989, 112:133–146.CrossRefGoogle Scholar
  7. 7.
    Lublin FD, Reingold SC: Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: relations between study investigators, advisors, and sponsors. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1997, 48:572–574.PubMedGoogle Scholar
  8. 8.
    Soilu-Hänninen M, Airas L, Mononen I, et al.: 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 2005, 11:266–271.PubMedCrossRefGoogle Scholar
  9. 9.
    Tremlett H, van der Mei IA, Pittas F, et al.: Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 2008, 31:271–279.PubMedCrossRefGoogle Scholar
  10. 10.
    Munger KL, Levin LI, Hollis BW, et al.: Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006, 296:2832–2838.PubMedCrossRefGoogle Scholar
  11. 11.
    Burton JM, Kimball S, Vieth R, et al.: A phase I/II dose-escalation trial of oral vitamin D3 with calcium supplementation in patients with multiple sclerosis. Program and abstracts of the ECTRIMS 2008: 24th Congress of the European Committee for Treatment and Research in Multiple Sclerosis. Montreal, Canada. September 17–20, 2008.Google Scholar
  12. 12.
    Jacobs LD, Beck RW, Simon JH, et al.: Intramuscular interferon beta 1-a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000, 343:898–904.PubMedCrossRefGoogle Scholar
  13. 13.
    Comi G, Filippi M, Barkhof F, et al.; Early Treatment of Multiple Sclerosis Study Group: Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study. Lancet 2001, 357:1576–1582.PubMedCrossRefGoogle Scholar
  14. 14.
    Kappos L, Polman CH, Freedman MS, et al.: Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006, 67:1242–1249.PubMedCrossRefGoogle Scholar
  15. 15.
    The IFNβ Multiple Sclerosis Study Group: Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. 1. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993, 43:655–661.Google Scholar
  16. 16.
    Jacobs LD, Cookfair DL, Rudick RA, et al.: Multiple Sclerosis Collaborative Research Group (MSCRG): Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996, 39:285–294.PubMedCrossRefGoogle Scholar
  17. 17.
    Ebers GC, PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998, 352:1498–1504.CrossRefGoogle Scholar
  18. 18.
    Durelli L, Verdun E, Barbero P, et al.; Independent Comparison of Interferon (INCOMIN) Trial Study Group: Every other day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomized multicenter study (INCOMIN). Lancet 2002, 359:1453–1460.PubMedCrossRefGoogle Scholar
  19. 19.
    Panitch H, Goodin DS, Francis G, et al.: Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002, 59:1496–1506.PubMedGoogle Scholar
  20. 20.
    Goodin DS, Frohman EM, Hurwitz B, et al.: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007, 68:977–984.PubMedCrossRefGoogle Scholar
  21. 21.
    Johnson KP, Brooks BR, Cohen JA, et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995, 45:1268–1276.PubMedGoogle Scholar
  22. 22.
    Johnson KP, Brooks BR, Cohen JA, et al.: Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998, 50:701–708.PubMedGoogle Scholar
  23. 23.
    Mikol DD, Barkhof F, Chang PK, et al.: Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the Rebif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008, 7:903–914.PubMedCrossRefGoogle Scholar
  24. 24.
    The BEYOND (Betaferon/Betaseron Efficacy Yielding Outcomes of a New Dose) Study. Available at Accessed February 2, 2009.
  25. 25.
    Combination therapy in patients with relapsing-remitting multiple sclerosis (MS): CombiRx. Available at Accessed February 2, 2009.
  26. 26.
    Polman CH, O’Connor PW, Havrdova E, et al., for the AFFIRM investigators: A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006, 354:899–910.PubMedCrossRefGoogle Scholar
  27. 27.
    Hyman N, Barnes M, Bhakta B, et al.: Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomized, double-blind, placebo controlled dose ranging study. J Neurol Neurosurg Psychiatry 2000, 68:707–712.PubMedCrossRefGoogle Scholar
  28. 28.
    Schurch B, De Seze M, Denys P, et al.: Botulinum toxin A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo-controlled 6-month study. J Urol 2005, 174:196–200.PubMedCrossRefGoogle Scholar
  29. 29.
    Smith CP, Nishiguchi J, O’Leary M, et al.: Single institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. J Urol 2005 65:37–41.CrossRefGoogle Scholar
  30. 30.
    Schuele SU, Kellinghaus C, Shook SJ, et al.: Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. Neurology 2005, 64:1086–1087.PubMedGoogle Scholar
  31. 31.
    Alusi SH, Worthington J, Glickman S, Bain PG: A study of tremor in multiple sclerosis. Brain 2001, 124:720–730.PubMedCrossRefGoogle Scholar
  32. 32.
    Alusi SH, Aziz TZ, Glickman S, et al.: Stereotactic lesional surgery for the treatment of tremor in multiple sclerosis: a prospective case-controlled study. Brain 2001, 124:1576–1589.PubMedCrossRefGoogle Scholar
  33. 33.
    Schuurman PR, Bosch DA, Bossuyt PM, et al.: A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med 2000, 342:461–468.PubMedCrossRefGoogle Scholar
  34. 34.
    Rietberg MB, Brooks D, Uitdehaag BM, Kwakkel G: Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev 2005, CD003980.Google Scholar
  35. 35.
    Goodman AD, Brown TR, Cohen JA, et al.: Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008, 71:1134–1141.PubMedCrossRefGoogle Scholar
  36. 36.
    Andrews KL, Husmann DA: Bladder dysfunction and management in multiple sclerosis. Mayo Clin Proc 1997, 72:1176–1183.PubMedCrossRefGoogle Scholar
  37. 37.
    Arnett PA, Barwick FH, Beeney JE: Depression in multiple sclerosis: review and theoretical proposal. J Int Neuropsychol Soc 2008, 14:691–724.PubMedGoogle Scholar
  38. 38.
    Efficacy and safety of fingolimod in patients With relapsing-remitting multiple sclerosis with optional extension phase (TRANSFORMS). Available at Accessed January 27, 2009.
  39. 39.
    FTY720 in Patients With Primary Progressive Multiple Sclerosis (INFORMS). Available at Accessed January 27, 2009.
  40. 40.
    Efficacy and safety of fingolimod (FTY720) in patients with relapsing-remitting multiple sclerosis (FREEDOMS II). Available at Accessed January 27, 2009.
  41. 41.
    The CAMMS223 Trial Investigators: Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 2008, 359:1786–1801.CrossRefGoogle Scholar
  42. 42.
    Comparison of alemtuzumab and Rebif multiple sclerosis, Study Two (CARE-MS II). Available at Accessed January 27, 2009.
  43. 43.
    Hauser SL, Waubant E, Arnold DL, et al.: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008, 358:676–688.PubMedCrossRefGoogle Scholar
  44. 44.
    CLARITY — Safety and efficacy of oral cladribine in subjects with relapsing-remitting MS. Available at Accessed January 27, 2009.
  45. 45.
    Phase II cladribine add-on to interferon-beta (IFN-β) therapy in MS subjects with active disease (ONWARD). Available at Accessed January 27, 2009.
  46. 46.
    Study of teriflunomide in reducing the frequency of relapses and accumulation of disability in patients with multiple sclerosis (TEMSO). Available at Accessed January 27, 2009.
  47. 47.
    Phase III study with teriflunomide versus placebo in patients with first clinical symptom of multiple sclerosis. Available at Accessed January 27, 2009.
  48. 48.
    Weinshenker BG, O’Brien PC, Petterson TM, et al.: A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999, 46:878–886.PubMedCrossRefGoogle Scholar
  49. 49.
    Nishikawa M, Ichiyama T, Hayashi T, et al.: Intravenous immunoglobulin therapy in acute disseminated encephalomyelitis. Pediatr Neurol 1999, 21:583–586.PubMedCrossRefGoogle Scholar
  50. 50.
    Murthy SN, Faden HS, Cohen ME, Bakshi R: Acute disseminated encephalomyelitis in children. Pediatrics 2002, 110(2 Pt 1):e21.PubMedCrossRefGoogle Scholar
  51. 51.
    Apak RA, Anlar B, Saatci I: A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment. Brain Dev 1999, 21:279–282.PubMedCrossRefGoogle Scholar
  52. 52.
    Banwell B, Reder AT, Krupp L, et al.: Safety and tolerability of interferon beta-1b in pediatric multiple sclerosis. Neurology 2006, 66:472–476.PubMedCrossRefGoogle Scholar
  53. 53.
    Ghezzi A, Amato MP, Capobianco M, et al.: Disease modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study. Mult Scler 2005, 11:420–424.PubMedCrossRefGoogle Scholar
  54. 54.
    Banwell B: Treatment of children and adolescents with multiple sclerosis. Expert Rev Neurother 2005, 5:391–401.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group, LLC 2009

Authors and Affiliations

  1. 1.Corinne Goldsmith Dickinson Center for Multiple SclerosisNew YorkUSA

Personalised recommendations